Sarka Stehlikova
Director, Biologics Core Technologies SOTIO Biotech
Sarka has 12 years of experience in antibody discovery, engineering and CMC. She works currently at SOTIO Biotech where she leads the Biologics Core Technologies department and is responsible for design and engineering, drug discovery efforts and developability assessment of biologics, including next-gen bispecific ADCs.
Seminars
Tuesday 24th February 2026
Fine-Tuning Next-Generation Bispecific ADCs for Improved Efficacy & Safety
2:00 pm
- Leveraging site-specific conjugation and linker-payload technologies to advance a pipeline of ADCs
- Exploring preclinical development of bispecific ADCs aspiring to minimise on-target toxicity and overcome tumour heterogeneity
- Optimising the bispecific format for optimal effect on tumour cells with varying antigen expression and discussing translation of functional in vitro data into in vivo efficacy
